Dr Sharissa Louise Latham

Following the completion of her PhD at the University of Sydney in 2015, Dr. Sharissa Latham undertook a postdoctoral position in the Institute for Biophysical Chemistry at Hannover Medical School, Germany. During this time, Dr. Latham’s research investigated the biology underlying several rare diseases and she was responsible for co-leading a study that identified a novel autosomal-dominant disorder, known as ACTB-Associated Syndromic Thrombocytopenia.

‍

Dr Latham was recruited to the Garvan Institute in 2018, where she completed a second post-doctoral position in oncogenic signalling with A/Prof David Croucher before starting her own research group in 2023. Throughout this time, Dr Latham has pioneered a large-scale drug discovery program aimed at identifying novel therapeutic vulnerabilities to treat metastatic triple-negative breast cancer. This drug discovery program has now expanded to other highly aggressive cancers for which there are limited therapies available, including rare Appendiceal cancers and Ovarian Cancers, for which she has recently received Cancer Council NSW funding.  

‍